Breast Cancer

This literature review of 10 studies found that anemia is common during NAC, with restrictive transfusion thresholds and intravenous iron supplementation showing favorable safety profiles, while ESA use and blood transfusions raised concerns about oncologic outcomes.

A decision tree cost-utility analysis found ICG more cost-effective than methylene blue for SLNB in breast cancer (ICER $4,044/QALY), with Monte Carlo simulation showing an 80% probability of ICG superiority.

Compared with wire-guided needle localization, MOLLI localization was associated with shorter median OR delays, fewer overall delays, and an estimated combined annual opportunity cost benefit of nearly $673,000.

Early adoption of the MOLLI wireless localization system demonstrated a rapid learning curve, fewer missed biopsy clips, and a significant reduction in operating room delays compared with traditional needle localization.

In 161 biopsied breast masses, malignant lesions showed significantly higher E-strain ratios than benign lesions (3.51 vs 1.93), with progressive increases across BI-RADS categories, supporting elastography as an adjunct to biopsy decision-making.

Learn how ctDNA liquid biopsies sharpen prognosis, detect residual disease, and guide breast cancer care, plus where evidence says to wait.

This literature review and institutional case report describes primary NECB with synchronous pancreatic and liver metastases as an extraordinarily rare, aggressive phenotype requiring multidisciplinary management driven by tumor biology rather than surgery.

Post-surgical pyoderma gangrenosum was successfully managed following bilateral mastectomy after clinical recognition prompted a shift to immunosuppressive therapy, avoiding further surgical debridement and achieving eventual wound healing.

The MagUS magnetically-guided ultrasound biopsy technique enabled successful sentinel lymph node biopsy de-escalation in 7 patients who preferred axillary evaluation to surgical staging, with all pathology returning negative.

In 42 patients with DCIS undergoing breast-conserving surgery, 71.4% had detectable disseminated cancer cells in bone marrow, with residual-risk DCISionRT score significantly correlated with higher DCC burden compared with low- and elevated-risk groups.

This survey-based TIP study examines patient-perceived barriers to home recovery after mastectomy within a single ERAS-enabled hospital system, aiming to identify why patients decline same-day discharge despite being clinically eligible.

In 433 patients undergoing breast surgery, median VAS pain scores declined from 2 on day 1 to 0 by day 30, with severe pain in only 7.4% and opioid use in 2.5%, supporting nonopioid-based analgesic protocols.

In 1153 women undergoing breast imaging and NCB, BIRADS 5 status, symptomatic presentation, and age over 70 years were associated with shorter time to biopsy, while socioeconomic and demographic factors were not significant predictors of delay.

In a retrospective multi-institution study of 267 early-stage breast cancer patients, the TumorSight Viz AI algorithm achieved landmark identification and measurement accuracy comparable to inter-radiologist variability, generating results in an average of 8 minutes per patient.

The first reported case of xanthogranulomatous mastitis in a pregnant patient was managed conservatively, avoiding surgery during pregnancy; a literature review of 24 cases found co-incidence of malignancy in 14% of excised lesions.

Routine intraoperative frozen section analysis of sentinel lymph nodes after neoadjuvant chemotherapy did not improve surgical outcomes and led to unnecessary axillary lymph node dissection in over half of intraoperatively positive cases.

In this prospective multicenter study, the next-generation MarginProbe device (MP2) achieved sensitivity of 76.8% and specificity of 49.1% for intraoperative lumpectomy margin assessment, meeting all predefined success criteria and earning FDA approval in September 2025.

Therapeutic mammoplasty with contralateral symmetrization showed low long-term local recurrence in early breast cancer, with failure to complete adjuvant therapy as the strongest modifiable predictor of recurrence.

In this single-center retrospective series of 45 patients with locally advanced breast cancer, preoperative 5-fraction ultra-hypofractionated radiotherapy yielded favorable clinical response in 46.6% and clinical downstaging in 92.9% of evaluable surgical cases.

This narrative review synthesizes evidence on breast cancer–related lymphedema prevention and management, finding that surgical mitigation strategies and coordinated radiation planning within multidisciplinary pathways reduce BCRL risk and improve survivorship outcomes.

Sherry Shen, MD, shares retrospective data on how GLP-1s influence overall survival and safety outcomes among patients with breast cancer.

In this retrospective cohort of 99 patients, PMRT-related post-reconstruction complications occurred in 25%, with chemotherapy receipt associated with significantly lower complication risk and no association found for BMI, cancer stage, or reconstruction type.

In an external blinded validation of 426 women with HR-positive, HER2-negative IBC at Royal Melbourne Hospital, a multi-omic test stratified patients by LRR risk and RT benefit, identifying subgroups who could safely omit RT and those with elevated risk who benefited significantly.

Results from the phase 3 ASCENT-03 and ASCENT-04 trials supported the FDA approval across both locally advanced or metastatic TNBC indications.

Findings from the phase 3 PATINA trial support the FDA approval of palbociclib plus trastuzumab with or without pertuzumab in this breast cancer population.